CRISPR-Cas12–based detection of SARS-CoV-2

An outbreak of betacoronavirus SARS-CoV-2 began in Wuhan, China in December 2019. COVID-19, the disease associated with infection, rapidly spread to produce a global pandemic. We report development of a rapid (<40 min), easy-to-implement and accurate CRISPR-Cas12-based lateral flow assay for dete...

Descripción completa

Detalles Bibliográficos
Autores principales: Broughton, James P., Deng, Xianding, Yu, Guixia, Fasching, Clare L., Servellita, Venice, Singh, Jasmeet, Miao, Xin, Streithorst, Jessica, Granados, Andrea, Sotomayor-Gonzalez, Alicia, Zorn, Kelsey, Gopez, Allan, Hsu, Elaine, Gu, Wei, Miller, Steve, Pan, Chao-Yang, Guevara, Hugo, Wadford, Debra A., Chen, Janice S., Chiu, Charles Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107629/
https://www.ncbi.nlm.nih.gov/pubmed/32300245
http://dx.doi.org/10.1038/s41587-020-0513-4
Descripción
Sumario:An outbreak of betacoronavirus SARS-CoV-2 began in Wuhan, China in December 2019. COVID-19, the disease associated with infection, rapidly spread to produce a global pandemic. We report development of a rapid (<40 min), easy-to-implement and accurate CRISPR-Cas12-based lateral flow assay for detection of SARS-CoV-2 from respiratory swab RNA extracts. We validated our method using contrived reference samples and clinical samples from US patients, including 36 patients with COVID-19 infection and 42 patients with other viral respiratory infections. Our CRISPR-based DETECTR assay provides a visual and faster alternative to the US CDC SARS-CoV-2 real-time RT-PCR assay, with 95% positive predictive agreement and 100% negative predictive agreement..

Ejemplares similares